Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells1

  title={Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells1},
  author={Sven Brode and Tim Raine and Paola Zaccone and Anne Cooke},
  journal={The Journal of Immunology},
  pages={6603 - 6612}
Regulatory T cells (Tregs) have been implicated as key players in immune tolerance as well as suppression of antitumor responses. The chemotherapeutic alkylating agent cyclophosphamide (CY) is widely used in the treatment of tumors and some autoimmune conditions. Although previous data has demonstrated that Tregs may be preferentially affected by CY, its relevance in promoting autoimmune conditions has not been addressed. The nonobese diabetic mouse spontaneously develops type-1 diabetes (T1D… 

Figures from this paper

Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes

It is reported that GA was effective in altering the clinical course of diabetes in cyclophosphamide-potentiated non-obese diabetic mice and ameliorated insulitis, which coincided with increased CD4+CD25+Foxp3+ T cell response in treated mice.

Upregulating CD4+CD25+FOXP3+ Regulatory T Cells in Pancreatic Lymph Nodes in Diabetic NOD Mice by Adjuvant Immunotherapy

It is demonstrated that CFA treatment ameliorates autoimmunity in diabetic NOD mice by up-regulating CD4+CD25+Foxp3+ regulatory T cells and increasing TGF-&bgr;1 production.

Immunomodulation Followed by Antigen-Specific Treg Infusion Controls Islet Autoimmunity

It is shown that Treg engraftment and therapeutic benefit in nonautoimmune models required ablative host conditioning, and nonablative, combinatorial regimens involving the anti-CD3 (αCD3), cyclophosphamide (CyP), and IAC (IL-2/JES6–1) antibody complex promoted engraftments of autoantigen-specific donor Tregs and controls islet autoimmunity without long-term immunosuppression.

CD28/CD154 Blockade Prevents Autoimmune Diabetes by Inducing Nondeletional Tolerance After Effector T-Cell Inhibition and Regulatory T-Cell Expansion

Immunotherapies that selectively suppress effector T-cells while permitting the development of natural regulatory mechanisms may have a unique role in establishing targeted long-standing immune protection and peripheral tolerance.

Cyclophosphamide Induces Dynamic Alterations in the Host Microenvironments Resulting in a Flt3 Ligand-Dependent Expansion of Dendritic Cells

It is demonstrated that CTX induces proliferation of DCs in BM prior to their expansion in the periphery, and targeting DCs at these phases would significantly improve their contribution to the clinical application of lymphodepletion to adoptive immunotherapy.

IL-2 Mediates CD4+ T Cell Help in the Breakdown of Memory-Like CD8+ T Cell Tolerance under Lymphopenic Conditions

BACKGROUND Lymphopenia results in the proliferation and differentiation of naïve T cells into memory-like cells in the apparent absence of antigenic stimulation. This response, at least in part due



Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization

Interleukin (IL)-2 plays a crucial role in the maintenance of natural immunologic self-tolerance. Neutralization of circulating IL-2 by anti–IL-2 monoclonal antibody for a limited period elicits

Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development

The pathogenesis of autoimmune diabetes in NOD mice is correlated with both an enhanced pathogenicity ofCD4+CD25− T cells and a decreased suppressive activity of CD4-CD25+ T cells, consistent with the role of CD54 in diabetes development.

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Most surprisingly, in the majority of patients with CLL treated with fludarabine-containing therapy regimens the inhibitory function of Treg cells was decreased or even abrogated.

Adaptive Islet-Specific Regulatory CD4 T Cells Control Autoimmune Diabetes and Mediate the Disappearance of Pathogenic Th1 Cells In Vivo1

The results suggest that adaptive regulatory CD4 cells may control diabetes in part by impairing the survival of islet-specific Th1 cells, and thereby inhibiting the localization and response of autoaggressive T cells in the pancreatic islets.

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

This is the first report demonstrating that CY, in addition to decreasing cell number, inhibits the suppressive capability of T(REGs), and the relevance of the loss of suppressor functionality and the changes in gene expression are discussed.

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

It is shown here that PROb tumor volume is correlated with an expansion of CD4+CD25+ regulatory T’lymphocytes in lymphoid tissues and the interest of regulatory T'cell depletion to sensitize established tumors to immunotherapy is pursued.

CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes

Data indicate that dendritic cells from NOD mice can generate CD25+ CD4+ T cells that suppress autoimmune disease in vivo, indicating that DCs from autoimmune mice can increase the number and function of antigen-specific, CD25-CD4+ regulatory T cells.

Characterization of Peripheral Regulatory CD4+ T Cells That Prevent Diabetes Onset in Nonobese Diabetic Mice1

The phenotypic and functional characteristics of protective CD4+ CD62L+ cells suggest they are different from Th2-, Tr1-, and NK T-type cells, reported to be implicated in the control of diabetes in NOD mice, and may represent a new immunoregulatory population.